These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 24045639

  • 1. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
    Rostan O, Gangneux JP, Piquet-Pellorce C, Manuel C, McKenzie AN, Guiguen C, Samson M, Robert-Gangneux F.
    mBio; 2013 Sep 17; 4(5):e00383-13. PubMed ID: 24045639
    [Abstract] [Full Text] [Related]

  • 2. IL-33/ST2 axis is involved in disease progression in the spleen during Leishmania donovani infection.
    Lamberet A, Rostan O, Dion S, Jan A, Guegan H, Manuel C, Samson M, Gangneux JP, Robert-Gangneux F.
    Parasit Vectors; 2020 Jun 22; 13(1):320. PubMed ID: 32571430
    [Abstract] [Full Text] [Related]

  • 3. Genetically Modified Live Attenuated Leishmania donovani Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice.
    Bhattacharya P, Dey R, Dagur PK, Kruhlak M, Ismail N, Debrabant A, Joshi AB, Akue A, Kukuruga M, Takeda K, Selvapandiyan A, McCoy JP, Nakhasi HL.
    Infect Immun; 2015 Oct 22; 83(10):3800-15. PubMed ID: 26169275
    [Abstract] [Full Text] [Related]

  • 4. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.
    Basu R, Bhaumik S, Haldar AK, Naskar K, De T, Dana SK, Walden P, Roy S.
    Infect Immun; 2007 Dec 22; 75(12):5956-66. PubMed ID: 17908806
    [Abstract] [Full Text] [Related]

  • 5. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
    Lehmann J, Enssle KH, Lehmann I, Emmendörfer A, Lohmann-Matthes ML.
    J Interferon Cytokine Res; 2000 Jan 22; 20(1):63-77. PubMed ID: 10670653
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
    Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A.
    J Immunol; 2011 Dec 15; 187(12):6417-27. PubMed ID: 22079980
    [Abstract] [Full Text] [Related]

  • 10. Live Attenuated Leishmania donovani Centrin Gene-Deleted Parasites Induce IL-23-Dependent IL-17-Protective Immune Response against Visceral Leishmaniasis in a Murine Model.
    Banerjee A, Bhattacharya P, Dagur PK, Karmakar S, Ismail N, Joshi AB, Akue AD, KuKuruga M, McCoy JP, Dey R, Nakhasi HL.
    J Immunol; 2018 Jan 01; 200(1):163-176. PubMed ID: 29187586
    [Abstract] [Full Text] [Related]

  • 11. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani.
    Melby PC, Yang YZ, Cheng J, Zhao W.
    Infect Immun; 1998 Jan 01; 66(1):18-27. PubMed ID: 9423834
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
    Dey R, Majumder N, Bhattacharyya Majumdar S, Bhattacharjee S, Banerjee S, Roy S, Majumdar S.
    Scand J Immunol; 2007 Dec 01; 66(6):671-83. PubMed ID: 18021365
    [Abstract] [Full Text] [Related]

  • 15. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R, Das P, De T, Chakraborti T.
    Immunobiology; 2013 Jan 01; 218(1):114-26. PubMed ID: 22440312
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-7 potentiates MAPK10-elicited host-protective vaccine against Leishmania donovani.
    Kumar S, Bodhale N, Patra SK, Sarode A, Zhao L, Sarkar A, Saha B.
    Cytokine; 2024 Feb 01; 174():156475. PubMed ID: 38134556
    [Abstract] [Full Text] [Related]

  • 17. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S, Smith DF, Kaye PM.
    J Immunol; 2000 Dec 15; 165(12):7064-71. PubMed ID: 11120835
    [Abstract] [Full Text] [Related]

  • 18. STAT4 is critical for immunity but not for antileishmanial activity of antimonials in experimental visceral leishmaniasis.
    Oghumu S, Gupta G, Snider HM, Varikuti S, Terrazas CA, Papenfuss TL, Kaplan MH, Satoskar AR.
    Eur J Immunol; 2014 Feb 15; 44(2):450-9. PubMed ID: 24242758
    [Abstract] [Full Text] [Related]

  • 19. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
    Mullen AB, Lawrence CE, McFarlane E, Wei XQ, Carter KC.
    Immunology; 2006 Nov 15; 119(3):348-54. PubMed ID: 16879623
    [Abstract] [Full Text] [Related]

  • 20. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.